Scientists hoped that aspirin, a blood thinner, could help hospitalized patients at an increased risk of blood clots forming, particularly in the lungs. The study was part of the university’s global RECOVERY trial investigating possible COVID-19 treatments and included nearly 15,000 hospitalized COVID-19 patients.
But 17 percent of people in both the group of patients receiving aspirin treatment and the group not receiving the drug died after 28 days in the hospital, CNBC reported.
“There has been a strong suggestion that blood-clotting may be responsible for deteriorating lung function and death in patients with severe COVID-19,” Martin Landray, PhD, a professor of medicine and epidemiology at the University of Oxford and one of the chief investigators in the study, told CNBC. “Aspirin is inexpensive and widely used in other diseases to reduce the risk of blood clots, so it is disappointing that it did not have a major impact for these patients. This is why large randomized trials are so important — to establish which treatments work and which do not.”
Read the full article here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
